Dutch start-up AIMM Therapeutics NV has inked a deal with a pharma partner, providing the means to ramp up development of its novel antibody platforms, and has attracted a leading immunologist and former head of the Novartis Institute for Biomedical Research, Jan de Vries, as CEO to spearhead that effort.